ReviewUrological research2005
Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?
Review in Urological research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 74 citations in OpenAlex.
- Chitosan does not reduce post-prandial urinary oxalate excretion.Urological research · 2006Trial
- Hyperoxaluria: Diagnosis and Treatment.The Urologic clinics of North America · 2025Review
- Engineered Oxalate Decarboxylase Boosts Activity and Stability for Biological Applications.ACS omega · 2025Article
- Association between intelectin-1 variation and human kidney stone disease in northeastern Thai population.Urolithiasis · 2021Article
- Induction of enteric oxalate secretion by Oxalobacter formigenes in mice does not require the presence of either apical oxalate transport proteins Slc26A3 or Slc26A6.Urolithiasis · 2020Article
- ALLN-177, oral enzyme therapy for hyperoxaluria.International urology and nephrology · 2019Article
- Expression of heterologous oxalate decarboxylase in HEK293 cells confers protection against oxalate induced oxidative stress as a therapeutic approach for calcium oxalate stone disease.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project.Microbiome · 2017Article
- Genome Sequence ofGenome announcements · 2017Article
- Screening of Oxalate Degrading Lactic Acid Bacteria of Food Origin.Italian journal of food safety · 2017Article
- Article
- Gut microbiota and oxalate homeostasis.Annals of translational medicine · 2017Article
- Response of germ-free mice to colonization with O. formigenes and altered Schaedler flora.Applied and environmental microbiology · 2016Article
- Manipulating the gut microbiota to maintain health and treat disease.Microbial ecology in health and disease · 2015Article
- Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.International urology and nephrology · 2013Review
- Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-δ activation.American journal of physiology. Cell physiology · 2013Article
- NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys.Oxidative medicine and cellular longevity · 2013Review
- Quantitative analysis of colonization with real-time PCR to identify the role of Oxalobacter formigenes in calcium oxalate urolithiasis.Urological research · 2012Article
- The construction of an oxalate-degrading intestinal stem cell population in mice: a potential new treatment option for patients with calcium oxalate calculus.Urological research · 2012Article
- Hyperoxaluria and rapid development of renal failure following a combined liver and kidney transplantation: emphasis on sequential transplantation.JIMD reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment options in patients with primary and secondary hyperoxaluria are limited and do not always lead to sufficient reduction in urinary oxalate excretion. Intestinal oxalate degrading bacteria are capable of degrading oxalate to CO(2) and formate, the latter being further metabolized and excreted via the feces. It is speculated, that both endogenously produced, as well as dietary oxalate can be significantly removed via the intestinal tract. Oxalobacter formigenes, an obligate anaerobic microbe normally found in the intestinal tract has one oxalate degrading enzyme, oxalyl-CoA decarboxylase, which is also found in Bifidobacterium lactis. Other bacteria with possible oxalate degrading potency are lactic acid bacteria, as well as Enterococcus faecalis and Eubacterium lentum. However, specific therapeutic studies on humans are scarce and, except for Oxalobacter, data are not congruent. We found the oral application of Oxalobacter successful in patients with primary hyperoxaluria. However, long-term post-treatment follow-up of 1-2 years showed that constant intestinal colonization is not achieved in most patients. In one patient with constant colonization, urinary oxalate excretion normalized over time. Short-term studies with other bacteria such as lactic acid bacteria did not show a specific reduction in urinary oxalate excretion. O. formigenes might be a promising new therapeutic tool in patients with primary and secondary hyperoxaluria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.